Eye fluid analysis may unlock clues for untreated form of macular degeneration

NCT ID NCT03418220

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined inflammation markers in the fluid from the eyes of 82 people with different stages of age-related macular degeneration (AMD) and a control group without AMD. Researchers collected samples during cataract surgery and tested for 27 inflammation-related molecules. The goal was to identify specific patterns that could help understand the dry (atrophic) form of AMD, for which no treatment currently exists, and potentially guide future therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If specific inflammation markers are found in atrophic AMD, this could point toward new targeted treatments for a form of the disease that currently has no therapy.
What could go wrong
This is an observational study, not a treatment trial. It is small (82 participants) and only looks at markers in eye fluid, so any link to future therapies is uncertain and far off.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATROPHIC AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital de la Croix-Rousse

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.